Den progressionsfri overlevelse efter 6 måneder i intent- to- treat- populationen var 80% (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab).
Progression-free survival at 6 months in the intent-to-treat population was 80% (XELIRI plus bevacizumab) versus 74% (XELOX plus bevacizumab).